206 related articles for article (PubMed ID: 32252423)
1. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
MacDougall K; Spyropoulos AC
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
3. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.
Al Yami MS; Kurdi S; Abraham I
J Blood Med; 2018; 9():25-34. PubMed ID: 29503590
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.
Spyropoulos AC; Ageno W; Cohen AT; Gibson CM; Goldhaber SZ; Raskob G
Thromb Haemost; 2020 Jun; 120(6):924-936. PubMed ID: 32492724
[TBL] [Abstract][Full Text] [Related]
7. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of betrixaban.
Huisman MV; Klok FA
Eur Heart J Suppl; 2018 May; 20(Suppl E):E12-E15. PubMed ID: 29977164
[TBL] [Abstract][Full Text] [Related]
9. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
[TBL] [Abstract][Full Text] [Related]
10. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
Beyer-Westendorf J; Verhamme P; Bauersachs R
Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
[TBL] [Abstract][Full Text] [Related]
11. New paradigms in venous thromboprophylaxis of medically ill patients.
Spyropoulos AC; Raskob GE
Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
[TBL] [Abstract][Full Text] [Related]
12. The use of direct oral anticoagulants for extended duration thromboprophylaxis in medically ill patients: a systematic review and meta-analysis.
Alshouimi RA; Al Rammah SM; Alzahrani MY; Badreldin HA; Al Yami MS; Almohammed OA
J Thromb Thrombolysis; 2019 Oct; 48(3):422-429. PubMed ID: 31222563
[TBL] [Abstract][Full Text] [Related]
13. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
[TBL] [Abstract][Full Text] [Related]
14. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
[TBL] [Abstract][Full Text] [Related]
15. Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.
Ageno W; Hunt BJ
Eur Heart J Suppl; 2018 May; 20(Suppl E):E6-E11. PubMed ID: 29977163
[TBL] [Abstract][Full Text] [Related]
16. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
17. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
[TBL] [Abstract][Full Text] [Related]
18. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
Jamil A; Jamil U; Singh K; Khan F; Chi G
Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
[No Abstract] [Full Text] [Related]
20. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG; DeRemer CE; Smith SM; Gums JG
Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
